Debridement composition

Abstract

The disclosed technology relates to a wound dressing comprising an absorbent layer impregnated with or coated with a composition comprising a chelating agent, an amphoteric surfactant, and an anionic surfactant. The present invention also relates to methods and uses of the wound dressing.

Description

[Technical Field]

[0001] The present disclosure relates to the field of wound care, and in particular to compositions, wound dressings or other debridement formulations or aids for promoting and enhancing the natural cleansing mechanisms of autolytic debridement. [Background technology]

[0002] The physiology of the skin makes it an extremely resilient organ. The outer layer (stratum corneum) consists of scales formed from dead epithelial cells compressed flat by skin oils (sebum). The stratum corneum provides a flexible and effective waterproof barrier. Although elastic and resilient, because it is simply a compressed layer, it can be eroded by repeated friction or chemical action, or torn by trauma, creating scars. When the outer protective layer is removed, nerve endings are exposed, causing pain. Loss of the barrier leads to leakage of body fluids (exudation), leaving the underlying tissues vulnerable to microbial invasion.

[0003] Uncontaminated and acute wounds usually heal naturally with the aid of simple, supportive physical means, such as protective dressings. Autolytic (spontaneous, biochemically mediated) debridement of nonviable tissue is part of the natural acute wound healing process. However, treatment of contaminated traumatic, necrotic, and chronic wounds can be more difficult, and autolytic debridement may be insufficient. Removal of contaminated, nonviable tissue is often necessary before normal healing can be restored. While qualified medical professionals may be able to perform mechanical and / or sharp debridement to remove this nonviable material, nurses and less qualified caregivers may not be qualified or trusted to perform such tasks. Under these circumstances, less invasive debridement techniques are required. It is well understood that wound irrigation between dressing changes can aid in the mechanical removal of some material, and that the use of moisture-donating products and / or moisture-retaining dressings can facilitate autolytic debridement. However, autolytic debridement can be a slow process, and wounds containing nonviable tissue are highly susceptible to microbial growth and infection. Therefore, enhancing or accelerating autolytic debridement is desirable. Nonviable tissue types can include necrotic (dead) tissue, scab (granulation and accumulation of nonviable epithelial cells in a chronic wound environment), and biofilm (microbial material containing viable microorganisms and associated self-produced mucus or extracellular polymeric substances (EPS)). Biofilm is viable microbial tissue that can rapidly recover and grow, returning to its original state within days or hours. Scab is the result of the inflammatory phase of wound healing and contains dead or excess leukocytes, fibrin / fibroblasts, cellular debris / healing components, and liquefied devitalized tissue. Scab can provide a nutrient source for bacterial cells and an environment suitable for their growth, subsequently enabling biofilm formation. Necrotic tissue is an additional source of cellular debris in the form of fibrous proteins (e.g., collagen) and proteoglycans (components of the extracellular matrix). As a result, failure to properly prepare the wound bed by removing toxic waste materials such as scab and necrotic tissue has been shown to impede healing.The accumulation of such tissue, commonly associated with chronic wounds, plus poorly controlled microbial growth and subsequent biofilm formation, is thought to be an important factor in why some wounds fail to heal.

[0004] Therefore, there is a need for a composition that can enhance autolytic debridement. Such a composition can control biofilms before infection occurs. It is desirable for wound dressings to have a composition that allows for exfoliation, softening, and destruction of nonviable material, which is believed to further enhance the ability of absorbent materials to mechanically remove such material from the wound bed, thereby promoting healing.

[0005] While the use of surface-active agents (surfactants) may seem like an obvious choice to aid in the removal of unwanted material, they can be potentially harmful (cytotoxic—locally causing the death of cells involved in healing or systemically toxic) and require careful consideration of compatibility with other treatments used simultaneously. Antibiofilm agents also need to be considered, as well as the tonicity and pH of the wound environment. Thus, formulating enhanced autolytic debridement is complex and requires more than an adaptive or additive approach. Restoring barrier function, normal tonicity, and pH are necessary to minimize pain and delayed healing.

[0006] When active debridement techniques, such as biological (maggot or enzymatic), sharp surgical, or other mechanical debridement techniques, are not applicable, the current practice known in the art is to promote autolytic debridement. This is believed to be achieved by the use of occlusive and / or moist wound dressings with brief wound irrigation at the time of dressing change to remove unwanted material from the wound environment by fluid flow.

[0007] Wound cleansing compositions are disclosed, for example, in U.S. Patent No. 5,284,833. This describes a physiologically compatible aqueous wound cleansing composition that passes both the Draize eye irritation test and the primary skin irritation test, comprising, by weight, about 0.01 to about 50% surfactant to provide the composition with a surface tension of less than about 30 dynes / cm; about 0.05 to about 10% osmolality adjusting agent to provide the composition with an osmolality of about 200 to about 320 mOs / L; about 0.05 to about 3% buffering agent to maintain the pH of the composition in the range of about 6 to about 7.7; and a sufficient amount of water necessary to establish the above characteristics. While safety is fully considered, U.S. Patent No. 5,284,833 does not address the issue of biofilms or the transient nature of irrigation products.

[0008] U.S. Patent Application Publication No. US2017347661(A1) describes a composition comprising an antibacterial metal ion and a quaternary cationic surfactant. The composition disrupts biofilm EPS, thereby enhancing the effectiveness of the antiseptic action of the metal ion and reducing the risk of infection. There is no mention of disrupting or removing non-biofilm tissue. Summary of the Invention

[0009] There is a need for formulations aimed at enhancing wound debridement with minimal intervention that can be used in any situation. In some instances, when appropriate medical supervision is available, it is beneficial to have antibacterial compositions and dressings. However, in other instances, antibacterial agents may not be necessary because debridement and wound cleansing can minimize or prevent biofilm formation.

[0010] In one embodiment, the disclosed technology relates to a composition comprising a chelating agent, an amphoteric surfactant, and an anionic surfactant.

[0011] In one embodiment, the composition further comprises a non-ionic surfactant.

[0012] The composition may be impregnated, coated, or disposed on a device that is placed in direct contact with the wound. The device may include a wound dressing or a debridement tool. Both the wound dressing and the debridement tool may have an absorbent layer.

[0013] The debridement tool may have an absorbent layer, which may be a natural or synthetic material and may be in the form of a liquid or solid foam or mousse, fabric, industrial cloth or brush.

[0014] The composition can be, for example, in the form of a mousse or foam that can be applied as a liquid and then generated in situ.Without being bound by theory, the mousse or foam can remain in the wound and function as a wound dressing that forms in situ.Alternatively, the composition can be pre-formed and removed during or after the debridement process; traditional foam formulations; woven fabric wipes that are woven to generate a looped fiber surface; nonwoven or calendared fabrics such as pads, wipes, or scrubbing brushes; brush-like fabrics or tools whose fibers are cut to create a flock-like finish or, for example, monofilament.

[0015] Materials known for making foams, fabrics, textiles and brushes are known in the art.

[0016] In one embodiment, the disclosed technology relates to a debridement tool as disclosed herein. The debridement tool may typically be used for mechanical debridement.

[0017] The debridement tool can be, for example, a sponge or a pad. Common materials used to manufacture sponges or pads are typically polyurethane foam, polypropylene foam, polyester foam, or polyvinyl alcohol (PVA) foam. Polyester foam can be useful for wipes.

[0018] In one embodiment, the disclosed technology relates to a wound dressing as disclosed herein. The wound dressing is typically capable of being debrided by autolysis.

[0019] In one embodiment, the disclosed technology relates to a wound dressing comprising an absorbent layer impregnated with or coated with a composition comprising a chelating agent, an amphoteric surfactant, and an anionic surfactant. The absorbent layer may be in direct contact with the wound, or the absorbent layer may have a wound contact layer between the absorbent and the wound. In one embodiment, the absorbent layer is in direct contact with the wound.

[0020] In one embodiment, the disclosed technology relates to a wound dressing comprising an absorbent layer impregnated with or coated with a composition comprising a chelating agent, an amphoteric surfactant, an anionic surfactant, and a nonionic surfactant.

[0021] As used herein, the term "hydrocarbyl" includes groups such as alkyl, aryl, aralkyl, alkaryl, cycloalkyl, or alkenyl, which may be straight or branched chain and / or saturated or unsaturated, or may be ester derivatives thereof. In one embodiment, hydrocarbyl may include straight or branched chain alkyl or alkenyl groups, typically alkyl groups.

[0022] The amounts of the composition components are given based on weight percent (wt%) and areal density (weight per area) depending on the formulation and application. For example, % w / w may be most appropriate for fluid formulations such as liquids, gels, or mousses, while areal density may be appropriate for flat sheet dressings. In the examples, 150 gm -2 of fabric is used, and therefore the areal density basis is calculated by multiplying the wt% by a factor of 1.5.

[0023] Anionic surfactants The disclosed technology defines anionic surfactants. In different embodiments, the anionic surfactants may be present at 0.05 to 1.5 wt%, or 0.1 to 1 wt%, or 0.1 to 0.5 wt%.

[0024] In terms of areal density, the amount of anionic surfactant is 0.075 to 2.25 gm -2 , or 0.15 to 1.5 gm -2 , or 0.15 to 0.75 gm -2 It could be.

[0025] Anionic surfactants may include lipophilic oligomeric hydrocarbons and / or polyethoxylates with negatively charged hydrophilic head groups, such as carboxylates, sulfonates, sulfonate esters, sulfated esters, sulfated amides, carboxylated amides, or phosphates, all forms of anionic head groups. Examples include fatty acids or fatty acid salts, glutamate, sulfosuccinate, sarcosine, sarcosinate, isethionate, and taurate.

[0026] The anionic surfactants may be salts, or hydrocarbyl, or hydrocarbyl ester derivatives thereof, where the hydrocarbyl groups contain from 6 to 24, or 8 to 24, or 10 to 20 carbon atoms, and may typically be in the form of a salt.

[0027] In one embodiment, the anionic surfactant may include sulfosuccinate, sarcosine, glutamate.

[0028] An example of a sarcosine is sodium lauroyl sarcosinate.

[0029] For example, the sulfosuccinate may include disodium lauryl sulfosuccinate.

[0030] An example of a glutamate is sodium cocoyl glutamate.

[0031] In one embodiment, the anionic surfactant comprises a fatty acid or a fatty acid salt.

[0032] The fatty acid or fatty acid salt may be a C8-24 fatty acid or fatty acid salt or a mixture thereof. The salt may be composed of a fatty acid and an alkali metal or alkaline earth metal, typically an alkali metal. The alkali metal may include, for example, sodium or potassium, typically sodium.

[0033] C8-20 fatty acids can have 10 to 20 or 12 to 18 carbon atoms.

[0034] The fatty acid or fatty acid salt may be saturated or unsaturated. When unsaturated, the unsaturation may be mono- or di-unsaturated, i.e., the fatty acid is a mono- or di-unsaturated fatty acid.

[0035] Unsaturated fatty acids can contain cis- or trans-double bonds.

[0036] In one embodiment, the fatty acid or fatty acid salt is a fatty acid having 12 to 18 carbon atoms, monounsaturation, and is classified as a monosaturated fatty acid.

[0037] Examples of fatty acids include stearic acid, ricinoleic acid, oleic acid, eladic acid, petroleolic acid, palmitic acid, erucic acid, behenic acid, lauric acid, myristic acid or linoleic acid (e.g., 9,11-linoleic acid or 9,12-linoleic acid).

[0038] In one embodiment, the fatty acid may be selected from oleic acid, elaidic acid, or petroleum acid.

[0039] In one embodiment, the fatty acid may be selected from oleic acid or elaidic acid, typically oleic acid.

[0040] The fatty acid can be a diunsaturated fatty acid, such as 9,12-linoleic acid, and the salt is sodium linoleate.

[0041] amphoteric surfactants In one embodiment, the amphoteric surfactant is present at 0.01 to 1.5 wt%, or 0.02 to 0.8 wt%, or 0.05 to 0.5 wt%.

[0042] In terms of surface density, the amount of amphoteric surfactant is 0.015 to 2.25 gm -2 , or 0.03 to 1.2 gm -2 , or 0.075 to 0.75 gm -2 It could be.

[0043] In one embodiment, the amphoteric surfactant is present in an amount of 0.05 to 0.4 wt% (or 0.075 to 0.6 gm -2 ) can exist.

[0044] Amphoteric surfactants can include hydrocarbyl amphoacetates, alkenyl amphoacetates, hydrocarbyl amphodiacetates, alkenyl amphodiacetates, hydrocarbyl amphopropionates, hydrocarbyl amphodipropionates, or hydrocarbyl amphohydroxypropylsultaines, where the hydrocarbyl and alkenyl groups contain 6 to 24, or 8 to 24, or 10 to 20 carbon atoms. Typically, amphoteric surfactants have an alkali metal counterion, such as sodium, or ammonium.

[0045] Specific examples of amphoteric surfactants include sodium cocoamphoacetate, or cocoamidopropyl betaine, lauryl betaine, and hydroxysultaine. In one embodiment, the amphoteric surfactant can be sodium cocoamphoacetate.

[0046] chelating agents The technology disclosed herein includes a chelating agent as defined herein. The chelating agent may be in the form of a salt containing a negatively charged ion and a positively charged ion. The positively charged ion may be ammonium or an alkali metal from Group 1 of the periodic table, such as sodium or potassium.

[0047] In different embodiments, the chelating agent may be present at 0.01 to 1 wt%, or 0.1 to 0.75 wt%, or 0.1 to 0.5 wt%.

[0048] Regarding areal density, the amount of chelating agent is 0.015 to 1.5 gm -2 , or 0.15 to 1.125 gm -2 , or 0.15 to 0.75 gm -2 It could be.

[0049] The wound dressings disclosed herein may be impregnated or coated with a chelating agent, such as citrate or citric acid, tartrate or tartaric acid, tartolamide or tartolimide, lactate or lactic acid, maleate or maleic acid, glycolate or glycolic acid, oxalate or oxalic acid, gluconate or gluconic acid, phosphates, such as orthophosphate, polyphosphate, pyrophosphate, or hydroxy-carboxylic acid esters, including phosphates. These may include amines or amides, acids, or salts thereof, or aminopolycarboxylic acids such as ethylenediaminetetraacetic acid (EDTA), 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), nitrilotriacetic acid (NTA), fura-2, indo-1, pentetic acid, or sodium poly(aspartic acid) salts, hemoglobin, chlorophyll, or porphyrin, amines such as aminoethylethanolamine, diethylenetriamine, ethylenediamine, triethylenetetramine, tetramethylethylenediamine, cyclen, or deferoxamine.

[0050] In one particular embodiment, the chelating agent can be a salt of EDTA.

[0051] In a specific embodiment, the chelating agent can be EDTA, and the EDTA can be a mixture of di-, tri-, or tetra-basic salts of EDTA. EDTA can be, for example, disodium salt of EDTA, calcium disodium salt of EDTA, or tetrasodium salt of EDTA. In one embodiment, the salt of EDTA can be a mixture of salts of EDTA. Without being bound by theory, it is believed that EDTA, when present, can be in the form of di-, tri-, or tetra-basic salt, and the specific form of the salt depends on the pH of the wound site.

[0052] In one embodiment, EDTA may be added to the composition as tetrasodium EDTA.

[0053] In one embodiment, the chelate comprises an oxalate.

[0054] In one embodiment, the chelate comprises a hydroxy-carboxylic acid ester, salt, or amide thereof. When the chelating agent comprises a hydroxycarboxylic acid salt, the salt can be a citrate, such as mono-, di-, or tripotassium citrate, or mono-, di-, or tri-sodium citrate.

[0055] In one embodiment, the chelating agent comprises a hydroxycarboxylic acid salt, which may be mono- or di- or trisodium citrate, typically trisodium citrate.

[0056] In one embodiment, the chelate comprises a phosphate. The phosphate can be orthophosphate, pyrophosphate, tripolyphosphate, or a derivatized phosphate. The phosphate is typically in the form of a potassium or sodium salt. Examples of phosphates include dipotassium phosphate, potassium pyrophosphate, trisodium ascorbate phosphate, and sodium tripolyphosphate. An example of a derivatized phosphate is sodium ascorbyl phosphate.

[0057] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: 0.01 to 1 wt% (or 0.015 to 1.5 gm -2 ) a chelating agent present in 0.05 to 1.5 wt% (or 0.075 to 2.25 gm -2 ), and anionic surfactants present in 0.01 to 1.5 wt% (or 0.015 to 2.25 gm -2 ) an amphoteric surfactant present in

[0058] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: 0.1 to 0.75 wt% (or 0.15 to 1.125 gm -2 ) a chelating agent present in 0.1 to 1 wt% (or 0.15 to 1.5 gm -2 ), and anionic surfactants present in 0.02 to 0.8 wt% (or 0.03 to 1.2 gm -2 ) an amphoteric surfactant present in

[0059] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: 0.1 to 0.5 wt% (or 0.15 to 0.75 gm -2 ) a chelating agent present in 0.1~0.5wt% (0.15~0.75gm -2 ), and anionic surfactants present in 0.05 to 0.5 wt% (or 0.075 to 0.75 gm -2 ) an amphoteric surfactant present in

[0060] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool comprises: 0.1 to 0.5 wt% (or 0.15 to 1.5 gm -2 ) a chelating agent present in 0.1 to 0.5 wt% (or 0.15 to 1.5 gm -2 ), and anionic surfactants present in 0.05 to 0.4 wt% (or 0.075 to 0.6 gm -2 ) an amphoteric surfactant present in

[0061] In one embodiment, the composition impregnation that may be impregnated or coated in the wound dressing or debridement tool disclosed herein above may comprise: amphoteric surfactants which may be selected from hydrocarbyl-amphoacetates, alkenyl-amphoacetates, hydrocarbyl-amphoacetates, alkenyl-amphoacetates, hydrocarbylampho-propionates, hydrocarbylampho-dipropionates, or hydrocarbylamphohydroxypropylsultaines, wherein the hydrocarbyl group contains 6 to 24 or 8 to 24 carbon atoms; anionic surfactants which may be selected from fatty acids or fatty acid salts, sodium hydrocarbyl sulfanates, hydrocarbyl ammonium sulfanates, hydrocarbyl sulfosuccinates, hydrocarbyl sarcosines, hydrocarbyl sarcosinates, hydrocarbyl isethionates, and hydrocarbyl taurates; and The chelating agent may be selected from hydroxy-carboxylic acid esters or amides, acids, or salts thereof, including, for example, citrate, tartrate, tartolamide, or tartolimide, lactate, lactic acid, or glycolic acid, or glycolate, oxalate, gluconic acid, gluconate, phosphate, or salts of ethylenediaminetetraacetic acid (EDTA).

[0062] In one embodiment, the composition that may be impregnated or coated in the wound dressing or debridement tool disclosed herein above may comprise: amphoteric surfactants which may be selected from hydrocarbyl-amphoacetates, alkenyl-amphoacetates, hydrocarbyl-amphodiacetates, alkenyl-amphodiacetates, hydrocarbylampho-propionates, hydrocarbylampho-dipropionates, or hydrocarbylamphohydroxypropylsultaines, wherein the hydrocarbyl group contains 6 to 24 or 8 to 24 carbon atoms; an anionic surfactant, which may be selected from a fatty acid or fatty acid salt, a sulfosuccinate, a sarcosine, or a sarcosinate; and The chelating agent may be selected from oxalate, phosphate, citrate, or salts of EDTA.

[0063] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: EDTA salt, 0.01-1 wt% (or 0.015-1.5 gm -2 ) a chelating agent present in 0.05~1.5wt% (0.075~2.25gm -2 ), and anionic surfactants present in 0.01 to 1.5 wt% (or 0.015 to 2.25 gm -2 ) an amphoteric surfactant present in

[0064] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: EDTA salt, 0.1-0.75 wt% (or 0.15-1.125 gm -2 ) a chelating agent present in 0.1~1wt% (0.15~1.5gm -2 ), and anionic surfactants present in 0.02~0.8wt% (0.03~1.2gm -2 ) an amphoteric surfactant present in

[0065] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: EDTA salt, 0.1-0.5 wt% (or 0.15-0.75 gm -2 ) a chelating agent present in 0.1 to 0.5 wt% (or 0.15 to 0.75 gm -2 ) anionic surfactants present in 0.05 to 0.5 wt% (or 0.075 to 0.75 gm -2 ) an amphoteric surfactant present in

[0066] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: EDTA salt, 0.01-1 wt% (0.015-1.5 gm -2 ) a chelating agent present in an anionic surfactant which is a fatty acid or a fatty acid salt and is present at 0.2 to 1 wt %; 0.01 to 1.5 wt% (or 0.015 to 2.25 gm -2 ) an amphoteric surfactant present in

[0067] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: EDTA salt, 0.1-0.75 wt% (or 0.15-1.125 gm -2 ) a chelating agent present in an anionic surfactant that is a fatty acid or a fatty acid salt and is present at 0.25 to 0.7 wt %, and 0.02 to 0.8 wt% (or 0.03 to 1.2 gm -2 ) an amphoteric surfactant present in

[0068] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may include: EDTA salt, 0.1-0.5 wt% (or 0.15-0.75 gm -2 ) Chelating agents present in Fatty acids or fatty acid salts, 0.1 to 0.5 wt% (or 0.15 to 0.75 gm -2 ) anionic surfactants present in 0.05 to 0.5 wt% (or 0.075 to 0.75 gm -2 ) an amphoteric surfactant present in

[0069] In one embodiment, the composition that may be impregnated or coated on the wound dressing or debridement tool may further comprise a non-ionic surfactant, which may provide additional stability to the composition absorption layer that may be impregnated or coated on the wound dressing or debridement tool.

[0070] When present, the nonionic surfactant may be present at 0.01 to 0.7 wt%, or 0.05 to 0.5 wt%, or 0.1 to 0.3 wt%.

[0071] In terms of areal density, the amount of nonionic surfactant is 0.015 to 1.05 gm -2 , or 0.075 to 0.75 gm -2 , or 0.15 to 0.45 gm -2 It could be.

[0072] In one embodiment, the composition that may be impregnated in or coated on the wound dressing or debridement tool may further comprise a non-ionic surfactant, and the compositions disclosed herein may include: 0.01 to 1 wt% (or 0.015 to 1.5 gm -2 ) a chelating agent present in 0.05 to 1.5 wt% (or 0.075 to 2.25 gm -2 ) anionic surfactants present in 0.01 to 1.5 wt% (or 0.015 to 2.25 gm -2 ), and amphoteric surfactants present in 0.01 to 0.7 wt% (or 0.015 to 1.05 gm -2 ) nonionic surfactants that may be present.

[0073] Nonionic surfactants may include fatty acid esters, fatty acid amides, fatty acid ethoxylates, fatty acid amide ethoxylates, polyethoxylated compounds and polyalkyl ethers, polyhydroxyl compounds, hydrocarbyl glucosides and amine oxides. For example, polyoxyethylene fatty acid esters (polyoxyethylene sorbitan fatty acid esters), polyoxyethylene glycol fatty acid esters (polyoxyethylene glycol fatty acid esters), sucrose fatty acid esters (sucrose fatty acid esters), polyoxyethylene hydrogenated castor oils (polyoxyethylene hydrogenated castor oils) and polyoxyethylene alkyl ethers (polyoxyethylene alkyl ethers).

[0074] Non-ionic surfactants may include polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, PEG-40 stearate, PEG-100 stearate, sucrose stearate, sucrose myristate, isopropyl myristate, sucrose oleate, sucrose palmitate, sucrose laurate, laureth-21 (Laureth Field 21), ceteth-15 (Cetes Field 15), steareth-20 (Steareth Field 20), oleth-15 (Oleth Field 15), beheneth-20, and ceteareth-20 (Beheneth Field 20).

[0075] In one embodiment, the non-ionic surfactant may be a polysorbate, typically polysorbate 20.

[0076] The wound dressings disclosed herein can include at least one layer composed of foam, fabric, or technical fabric. For example, the fabric can be a non-woven or woven fiber layer, or a gel-forming fiber, or gauze.

[0077] The gauze may be made from cellulose, such as cotton or viscose.

[0078] In one embodiment, the absorbent layer of the wound dressing is a gel-forming fabric impregnated with or coated with a composition comprising a chelating agent, an amphoteric surfactant, and an anionic surfactant.

[0079] In one embodiment, the absorbent layer of the wound dressing is a gel-forming fabric impregnated with or coated with a composition comprising a chelating agent, an amphoteric surfactant, an anionic surfactant, and a nonionic surfactant.

[0080] In one embodiment, the disclosed technology relates to the use of a wound dressing for the treatment of a wound, wherein the wound contains a biofilm.

[0081] In one embodiment, the disclosed technology relates to the use of wound dressings to remove scabs, necrotic material or other foreign matter from a wound.

[0082] In one embodiment, the disclosed technology relates to the use of a wound dressing disclosed herein to prevent or minimize scab buildup in a wound by contacting the wound with the wound.

[0083] In one embodiment, the disclosed technology relates to a method of preventing or minimizing scab buildup in a wound by contacting the wound with a wound dressing disclosed herein, hi one embodiment, the wound dressing does not provide a chemically induced antiseptic effect.

[0084] In another embodiment, the disclosed technology relates to a composition comprising a chelating agent, an amphoteric surfactant, and an anionic surfactant for use in treating wounds, including chronic wounds, acute wounds, burns, wounds containing bacterial biofilms, or wound scabs. The composition can be as described above for any other embodiment of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0085] As used herein, the term "wound" includes injuries to living tissue, and may be caused by cuts, blows or other impacts, abrasion, pressure, heat, or chemicals; typically, the skin is cut or damaged. Wounds can often be described as chronic or acute. Acute wounds can occur as a result of surgery or trauma. Typically, if the injury is not too severe and the subject's other health is good, the wound will progress through well-defined healing stages within a predictable time. Chronic wounds begin as acute wounds. If an acute wound does not follow the normal healing pathway, it can become a chronic wound and recovery may be prolonged. It is believed that the transition from an acute wound to a chronic wound may be due to an insufficient immune response, for example, a patient's immune system is weakened, the wound is insufficiently perfused, or it is highly contaminated.

[0086] Chronic wounds may include, for example, venous ulcers (e.g., those occurring in the legs due to venous insufficiency), which account for the majority of chronic wounds and primarily affect the elderly; diabetic ulcers (e.g., ulcers of the foot or ankle); arterial ulcers (due to peripheral arterial disease); and pressure injuries due to immobility.

[0087] Wounds can also include deep tissue injury, a term proposed by the National Pressure Ulcer Advisory Panel (NPUAP) to describe a specific form of pressure ulcer. These ulcers have long been described by clinicians using terms such as purple pressure ulcers, potentially worsening ulcers, and bony prominence contusions.

[0088] The disclosed technology relates to the subject matter defined above.

[0089] The term "scab" is known to those skilled in the art and can be defined as a layer or mass of dead tissue that is separated from the surrounding living tissue, or tissue that is attached to a wound but can be removed like a wound, sore, or inflammation.

[0090] wound dressing The wound dressings disclosed herein may have a thickness of 0.5 to 20, or 2 to 10, or 3 to 7 mm.

[0091] In one embodiment, the wound dressing may be buffered to have a pH of 4 to 10, or 5 to 8, or 5.5 to 6.5.

[0092] The wound dressing may be composed of one or more layers selected from the group including an outer cover layer, an absorbent layer, a gel-forming fiber, an adhesive layer, a wound contact layer, a distribution layer, and combinations thereof.

[0093] In some embodiments, the wound dressing comprises one or more absorbent layers. The absorbent layer may be a foam or structure derived from a superabsorbent polymer material. When a foam is used, the foam may also function as a distribution layer.

[0094] In some embodiments, the wound dressing comprises an outer cover layer and one or more absorbent layers in combination with gel-forming fibers, which are typically in direct contact with the wound and therefore do not require an additional wound contact layer.

[0095] Gel-forming fibers refer to hygroscopic fibers that become wet, slippery, or gelatinous upon absorbing wound exudate. Gel-forming fibers can be of a type that retains its structural integrity upon absorbing exudate, or can be of a type that loses its fibrous form and becomes an amorphous or structureless gel. Gel-forming fibers are typically sodium carboxymethylcellulose fibers, chemically modified cellulose fibers, alkylsulfonate-modified cellulose fibers such as those described in WO 2012 / 061225, pectin fibers, alginate fibers, chitosan fibers, hyaluronic acid fibers, or fibers derived from other polysaccharide fibers or gums, and non-cellulose synthetic fibers such as poly(vinyl alcohol) and polyacrylates.

[0096] In one embodiment, the gel-forming fibers may be chemically modified carboxymethylcellulose fibers, typically sodium carboxymethylcellulose fibers. In one particular embodiment, the absorbent layer is a gel-forming fiber and the dressing does not include an additional dressing layer.

[0097] Gel-forming fibers are typically chemically modified cellulose fibers in the form of textiles, particularly the carboxymethylated cellulose fibers described in WO 00 / 01425. Sodium carboxymethylcellulose fibers typically have a degree of substitution of at least 0.05 carboxymethyl groups per glucose unit. Gel-forming fibers typically have an absorbency of at least 2 g (or at least 8 g, or at least 10 g) of 0.9% saline per gram of fiber (as measured by BS EN 13726-1 (2002) "Test methods for primary wound dressings," section 3.2 "Free swell absorptive capacity"). Carboxymethylated cellulose textiles typically have a degree of substitution (as defined in WO 00 / 01425) between 0.12 and 0.35, more typically between 0.20 and 0.30, to increase the absorbency of textiles made therefrom compared to unmodified cellulose. Particularly useful fabrics have an absorbency of between 10g / g and 30g / g of an isotonic aqueous solution measured by the method described in BS EN 13726-1 (2002).

[0098] Cellulose fabrics typically consist solely of cellulose fibers, but may also contain portions of textile or gel-forming fibers, which may be, for example, any known type of cellulose fiber and may include continuous filament yarns and / or staple fibers.

[0099] The absorbent layer may be in direct contact with the wound or may include a wound contact layer disposed between the wound and the absorbent layer, which is capable of absorbing exudate from the wound and transferring it to the absorbent layer.

[0100] In one embodiment, the wound contact layer comprises a gel-forming fiber or a silicone gel.

[0101] The outer cover layer of the dressing is a bacterial and viral barrier layer that typically prevents the ingress of liquids but allows moisture vapor to pass through.

[0102] In one embodiment, the absorbent layer may be a superabsorbent material, which may be a fibrous polymer or a nonwoven material.

[0103] The superabsorbent material may be a polyacrylate or a starch polymer.

[0104] In one embodiment, the absorbent layer can be a foam. The foam can have an open cell and / or closed cell structure. The foam can be derived from polyurethane, polyvinyl alcohol, collagen, chitosan. Typically, the foam can be a polyurethane foam.

[0105] The wound dressings disclosed herein may be prepared by a method comprising applying an absorbent layer composition comprising a chelating agent, an amphoteric surfactant, as disclosed herein.

[0106] Inclusion of the disclosed technology in a wound dressing or similar wound treatment device (e.g., a debridement tool) may be achieved by addition to the materials that make up the device or by addition to the finished device.

[0107] For example, if some or all of the components of the device are made of textiles, the technology could be: Add it to the dope (the liquid from which the fibers are spun (extruded)) Co-extrusion using the hot melt method · Cleaning the fibers in the soaking process Coating the formed fibers in liquid or solution form (wherein the solute can be removed by a drying process (known in the art - e.g., by forced air (or other gas - especially nitrogen if flammable solvents are involved); or by heat; or by heating and forced air)), or by passing the technology as a melt through a bath containing it. in liquid form or from a solution (wherein the solute may be removed by a drying process (known in the art - e.g. by forced air (or other gas - especially nitrogen if flammable solvents are involved); or by heat; or by heat and forced air)), or sprayed onto fibers formed as a molten liquid by hot melt ink jet methods applied as a powder coating which can promote adhesion by electrostatic effects or by increasing the adhesive tack of the receiving fibers (e.g. by partial hydration with moisture or by pre-treating the fibers with viscous liquids such as alcohols (e.g. hexanol), polyols (e.g. propane-1,2-diol or glycerol), hydrophilic hydrocarbons (e.g. poly(ethylene oxide))), or by the addition sequence of the invention itself (e.g. liquid surfactants, e.g. liquid fatty acids or fatty acid salts or liquid fatty acids which form salts in situ). Alternatively, if the device is pre-formed, for example as a fabric or foam, the technology may be applied by similar washing, coating, spraying or powder coating. Additionally, technology may be added by suspending the technology in a non-solvent and passing this through the device so that the suspended technology is mechanically trapped (i.e., actively added by filtering the technology); Alternatively, applied as an ink or dye by a printing process, e.g., a screen printing process, where application can be tightly controlled by the use of a screen. The print can be continuous, as achieved by flood coating, or more preferably as a discontinuous coating (regular or random pattern), as this has less impact on the device's porosity / breathability, flexibility, and ability to contour the complex topography of the wound bed at both the macroscopic (physiological) and microscopic (cellular) levels. Add as a separate layer: as a gel coating directly onto the wound device, e.g. by knife-over-roll or gravure coating techniques Alternatively, it may be cast as a film by similar coating techniques and then adhered to the wound device by making the device or film tacky, for example by moistening or adding an adhesive.

[0108] While the invention has been described in terms of its preferred embodiments, it is to be understood that various modifications will become apparent to those skilled in the art upon reading the specification. It is therefore to be understood that the invention disclosed herein is intended to cover such modifications as fall within the scope of the appended claims. [Example]

[0109] Example 1 The following examples are prepared and evaluated using simulated wound matrix compositions: A wound matrix is ​​prepared containing: [Table 1]

[0110] The simulated wound matrix is ​​crosslinked with 1.5% w / w calcium chloride for 18 hours on a solid-phase screening system (lid of a 96-peg microtiter plate). The pegs are immersed in the simulated wound matrix and quickly transferred to a calcium chloride bath to achieve crosslinking. Solutions of the test material are prepared at 1% w / w in a 96-well microtiter plate. After crosslinking, the pegs are placed in the wells and incubated at 37°C for 1 hour. Efficacy is characterized by the color change of the test solution caused by the destruction of the stained material and quantified by reading the absorbance of each solution at 595 nm. Results are shown relative to a 1% w / w aqueous solution of benzethonium chloride. Benzethonium chloride is a comparative example and is disclosed as part of the invention disclosed in WO 2012 / 136968. [Table 2]

[0111] It is also compared to a composition containing 0.39% w / w disodium EDTA and 0.135% w / w benzethonium chloride based on the formulation of a commercially available product (AQUACEL® Ag+ Extra), which is 30% less effective than the comparative example containing 1% benzethonium chloride.

[0112] Interpretation of results The HLB value predicts the cleaning effectiveness of a particular surfactant and is typically used as a selection guide, with higher HLB values ​​indicating greater predicted cleaning power. The ability of 1% w / w surfactants (with published HLB values) to disrupt simulated wound matrices does not correlate as expected. Sodium lauryl sulfate (SLS) is typically used as a standard for high cleaning power but is considered too harsh for routine use in personal care products. Disodium lauryl sulfosuccinate is considered a gentler alternative to SLS. Sodium oleate, the base of traditional bar soaps, is also generally recognized as a less effective cleanser than SLS, yet both sodium oleate and disodium lauryl sulfosuccinate are an order of magnitude more effective than SLS in disrupting simulated wound matrices. Similarly, sodium oleate and disodium lauryl sulfosuccinate are superior to benzalkonium chloride, cocoamidopropyl betaine, and poloxamer. TM 188, all of which are commonly used in liquid wound cleansing products. Therefore, indicating surfactant selection cannot be predicted by expected cleansing power or by the selection of commonly used ingredients.

[0113] The simulated wound matrix is ​​crosslinked and immobilized to the test surface by treatment with calcium chloride. Therefore, it seems obvious that this immobilization can be reversed by applying a compound that can compete with calcium for removal, e.g., by precipitating it as a sparingly soluble salt. It seems reasonable to assume that the lack of solubility of a calcium chelating agent can be used as a predictor of the agent's ability to remove calcium from the matrix and, therefore, its likelihood of matrix disruption. While calcium citrate (pH 7.5) is significantly more soluble than calcium oxalate at the same pH, citrate exhibits greater efficacy in simulated wound matrices than equivalent w / w oxalate. Furthermore, lowering the pH of the citric acid system to that of citric acid predictably increases calcium salt solubility and reduces matrix disruption, but is still more effective than sodium dihydrogen phosphate at higher pHs, where calcium salt solubility is low. Therefore, chelating agent selection cannot be predicted by calcium salt solubility or pH effects.

[0114] Example 2 The combined effect of surfactant and chelating agent was investigated when applied as a coating to a wound dressing (AQUACEL® Extra, ConvaTec PLC) that gels in the presence of water. A dressing without surfactant or chelating agent served as a control.

[0115] The test model of Example 1 is adapted to accommodate solid test materials. To achieve this, a simulated wound matrix is ​​cast onto a cellulose acetate sheet using a thin film applicator (1.5 mm wet thickness) and immersed face down in 1.5% w / w calcium chloride for 24 hours. The test dressing is applied to a 2 cm 2The coatings are cut into strips, hydrated with 1 ml of test solution A (BS EN 13726-1:2002), placed on a substrate, and incubated at 37°C for 18 hours. Effectiveness is characterized by the color change of the coating upon absorption of a liquid test matrix containing crystal violet dye. The solubilized fraction is quantified by extracting the crystal violet dye from the coating by adding 2 ml of 33% v / v acetic acid and extracting on a roller mixer for 30 minutes. The absorbance of each resulting solution is read at 595 nm. [Table 3] [Table 4]

[0116] Interpretation of results Test materials are listed as wt% of the dry coating. Because the coating in this example absorbs a large amount of aqueous liquid (approximately 23 g / g in this example) and moisture facilitates the function of the test material, dilution effects must be carefully considered. 1.0% w / w in this example approximates a 0.043% solution when tested as in Example 1. Therefore, a significant reduction in efficacy is expected. However, significant improvements are achieved over both the control and the cationic surfactant / chelator comparative example.

[0117] No improvement in performance is observed with individual or combined increases in the concentration of the test substances.

[0118] Example 3 As with any medical procedure, patient safety is paramount, and if the skin is damaged, there is always a risk that ingredients may strip essential lipids from the tissue and be absorbed into the local tissue or the blood and lymphatic circulation. To mitigate risk, it is recommended to select the safest candidates and minimize exposure to soluble or absorbable substances, which is most easily achieved by minimizing the applied concentration and / or density. Because of their relatively high cleansing power, anionic surfactants are considered harsh, while amphoteric surfactants are generally less effective but have better skin compatibility. Therefore, three additive systems for gelling dressings consisting of a chelating agent and two surfactants were investigated. Testing was performed as described in Example 2. [Table 5] [Table 6]

[0119] Interpretation of results No linear relationship between component concentration and activity was observed, suggesting that the addition of an amphoteric surfactant (sodium cocoamphoacetate) would reduce activity (compare Example 3B with 2C). However, with the addition of an amphoteric surfactant, a synergistic combination is found that allows significant reductions in both anionic surfactant and chelating agent while achieving significant improvement in performance over the base coating (Example 3D).

[0120] Conditional language such as "may," "could," "might," or "may," unless otherwise expressly stated or understood within the context in which it is used, is generally intended to convey that certain embodiments include certain features, elements, and / or steps, while other embodiments do not include certain features, elements, and / or steps. Thus, such conditional language is generally not intended to imply that features, elements, and / or steps are in any way required by one or more embodiments, or that one or more embodiments necessarily include logic for determining whether those features, elements, and / or steps are included or should be implemented in a particular embodiment, with or without user input or direction.

[0121] As used herein, the use of the singular includes the plural unless expressly stated otherwise. In this application, the use of "or" means "and / or" unless stated otherwise. Furthermore, the use of the term "including," as well as other forms such as "include," "includes," and "included," is not limiting.

[0122] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing Summary of the Disclosure and the following examples are exemplary and explanatory only and are not limiting of the claimed subject matter.

[0123] Each of the documents referred to above is incorporated herein by reference. Except in the examples, or where otherwise expressly indicated, all numerical values ​​herein specifying quantities of materials, device dimensions, and the like, should be understood to be modified by the term "about."

[0124] Unless otherwise specified, each chemical or composition referred to herein should be understood to be a commercial grade material that may include isomers, by-products, derivatives, and other such materials normally understood to be present in commercial grades.

[0125] Each of the documents referred to above is incorporated herein by reference. Except in the Examples, or where otherwise expressly indicated, all numbers herein designating amounts of materials, reaction conditions, molecular weights, numbers of carbon atoms, and the like, should be understood to be modified by the term "about."

[0126] As used herein, the phrase "consisting essentially of" permits the inclusion of substances that do not materially affect the basic and novel characteristics of the composition under consideration.

[0127] It should be understood that at least some of the figures and descriptions of the present disclosure have been simplified to focus on elements relevant for a clear understanding of the present disclosure, but that for clarity it may be necessary to omit other elements that would be understood by one of ordinary skill in the art, and descriptions of such elements are not provided herein because they are well known to those of ordinary skill in the art and do not necessarily facilitate a better understanding of the present disclosure.

Claims

1. 1. A wound dressing or debridement tool comprising an absorbent layer impregnated with or coated with a composition comprising a chelating agent, an amphoteric surfactant, and an anionic surfactant, the chelating agent is present at 0.01 to 1 wt % and comprises ethylenediaminetetraacetic acid (EDTA); the anionic surfactant is present at 0.05 to 1.5 wt % and comprises sodium oleate; and The amphoteric surfactant is present at 0.01 to 1.5 wt % and includes sodium cocoamphoacetate. The wound dressing or debridement tool.

2. 10. The wound dressing or debridement tool of claim 1, wherein the anionic surfactant is present at 0.1 to 1 wt%, or 0.1 to 0.5 wt%.

3. 3. The wound dressing or debridement tool of claim 1 or 2, wherein the anionic surfactant further comprises an anionic surfactant selected from a fatty acid or fatty acid salt, a sulfonate, a sulfosuccinate, a sarcosine, a sarcosinate, an isethionate, a glutamate, or a taurate.

4. 4. The wound dressing or debridement tool of any one of claims 1 to 3, wherein the amphoteric surfactant is present at 0.02 to 0.8 wt%, or 0.05 to 0.5 wt%.

5. 5. The wound dressing or debridement tool of any one of claims 1 to 4, wherein the amphoteric surfactant further comprises an amphoteric surfactant selected from hydrocarbyl-amphoacetates, alkenyl-amphoacetates, hydrocarbyl-amphodiacetates, alkenyl-amphodiacetates, hydrocarbylampho-propionates, hydrocarbylampho-dipropionates, or hydrocarbylamphohydroxypropylsultaines, wherein the hydrocarbyl and alkenyl groups contain from 6 to 24 or 8 to 24 carbon atoms.

6. 6. The wound dressing or debridement tool of any one of claims 1 to 5, wherein the chelating agent is present at 0.1 to 0.75 wt%, or 0.1 to 0.5 wt%.

7. 7. The wound dressing or debridement tool of any one of claims 1 to 6, wherein the chelating agent further comprises a chelating agent selected from a hydroxy-carboxylic acid ester or amide acid, or a salt thereof (e.g., citrate, tartrate, tartoramide, or tartolimide, gluconic acid, gluconate, lactate, lactic acid, glycolic acid, or glycolate), an oxalate, a phosphate, or a salt of ethylenediaminetetraacetic acid (EDTA).

8. The wound dressing may be impregnated or coated with a composition comprising: a chelating agent present at 0.1 to 0.75 wt %; an anionic surfactant present at 0.1 to 1 wt %, or Amphoteric surfactants present at 0.02-0.8 wt% 8. The wound dressing or debridement tool of any one of claims 1 to 7, comprising:

9. The wound dressing may be impregnated or coated with a composition comprising: a chelating agent present at 0.1-0.5 wt. %; Anionic surfactants present at 0.1-0.5 wt% Amphoteric surfactants present at 0.05-0.5 wt% 9. The wound dressing or debridement tool of any one of claims 1 to 8, comprising:

10. The wound dressing or debridement tool may be impregnated or coated with: 0.1 to 0.5 wt% (or 0.15 to 1.5 gm -2 ) a chelating agent present in 0.1 to 0.5 wt% (or 0.15 to 1.5 gm -2 ) anionic surfactants present in 0.05 to 0.4 wt% (or 0.075 to 0.6 gm -2 ) amphoteric surfactants present in 10. The wound dressing or debridement tool of any one of claims 1 to 9, comprising:

11. 11. The wound dressing or debridement tool of any one of claims 1 to 10, wherein the composition further comprises a non-ionic surfactant.

12. Nonionic surfactants are present in an amount of 0.01 to 0.7 wt% (or 0.015 to 1.05 gm -2 ), or 0.05 to 0.5 wt% (or 0.075 to 0.75 gm -2 ), or 0.1 to 0.3 wt% (or 0.15 to 0.45 gm -2 12. The wound dressing of claim 11, wherein the wound dressing is present in a

13. The wound dressing or debridement tool may be impregnated or coated with a composition comprising: 0.01 to 1 wt% (or 0.015 to 1.5 gm -2 ) a chelating agent present in 0.05 to 1.5 wt% (or 0.075 to 2.25 gm -2 ) anionic surfactants present in 0.01 to 1.5 wt% (or 0.015 to 2.25 gm -2 ) amphoteric surfactants present in 0.01 to 0.7 wt% (or 0.015 to 1.05 gm -2 ) a nonionic surfactant that may be present 13. The wound dressing or debridement tool of any one of claims 1 to 12, comprising:

14. 14. The wound dressing or debridement tool of any one of claims 11 to 13, wherein the non-ionic surfactant is selected from polyoxyethylene fatty acid esters (polyoxyethylene sorbitan fatty acid esters), polyoxyethylene glycol fatty acid esters (polyoxyethylene glycol fatty acid esters), sucrose fatty acid esters (sucrose fatty acid esters), polyoxyethylene castor bicarbonate oils and polyoxyethylene alkyl ethers (polyoxyethylene hydrogenated castor oil) ethers (polyoxyethylene alkyl ethers).

15. 15. The wound dressing or debridement tool of any one of claims 1 to 14, wherein the absorbent layer impregnated or coated with the composition comprises at least one layer composed of foam, absorbent material (typically superabsorbent), or gel-forming fibers.

16. 16. The wound dressing or debridement tool of any one of claims 1 to 15, wherein the wound dressing absorbent layer is a gel-forming fiber.

17. 17. The wound dressing or debridement tool of any one of claims 1 to 16, wherein the absorbent layer of the wound dressing is a gel-forming fiber, the fiber being a chemically modified carboxymethylcellulose fiber, typically sodium carboxymethylcellulose fiber.

18. A wound dressing which is a wound dressing according to any one of claims 1 to 17.

19. A debridement tool according to any one of claims 1 to 17.

20. 20. A wound dressing or debridement tool according to any one of claims 1 to 19 for use in preventing or minimising scab build-up in a wound by contacting the wound with the wound dressing or debridement tool according to any one of claims 1 to 19.

21. A wound dressing or debridement tool as described in any one of claims 1 to 19 for use in treating a chronic wound, acute wound or burn having a bacterial biofilm.

22. A wound dressing or debridement tool as described in any one of claims 1 to 19 for use in desquamating a wound, wherein the wound is a chronic wound, an acute wound or a burn.

Images